Nanjing-based central nervous system (CNS) drug developer, Neurodawn Pharmaceutical Co., Ltd, has announced the successful completion of a Series C financing round, raising hundreds of millions of renminbi. The funding was led by Nanjing Jiangning High Tech Zone Science and Technology Entrepreneurship Investment Management Co., Ltd and Huaxing Kangping Pharmaceutical Industry Private Equity Fund. The proceeds from this round will be allocated to accelerate the development of the company’s core pipeline, build innovative platforms, and expand its global business footprint.
Neurodawn Pharma’s Focus on CNS Diseases
Founded in 2020, Neurodawn Pharmaceutical has established a robust product pipeline targeting high-risk central nervous system-related diseases. These include stroke, intracranial tumors, cognitive impairment, emotional disorders, neuropathic pain, and cerebral small vessel disease. The company’s drug candidates are at various stages of development, with some in clinical trials and others in pre-clinical phases.- Flcube.com
